Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGTCNASDAQ:AHACNASDAQ:AYLANASDAQ:LOGCNASDAQ:MIRO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/AAHACAlpha Healthcare Acquisition$10.96$10.41$9.12▼$16.96$140.89MN/A341,126 shs298,128 shsAYLAAyala Pharmaceuticals$0.50+13,885.0%$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/ALOGCLogicBio Therapeutics$2.07$2.06$0.26▼$3.77$68.23M4.61652,526 shsN/AMIROMiromatrix Medical$3.39$3.38$0.91▼$4.35$92.95M0.0180,095 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%AHACAlpha Healthcare Acquisition0.00%0.00%0.00%0.00%0.00%AYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%LOGCLogicBio Therapeutics0.00%0.00%0.00%0.00%0.00%MIROMiromatrix Medical0.00%0.00%0.00%0.00%+171.20%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAHACAlpha Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic TechnologiesN/AN/AN/AN/AAHACAlpha Healthcare AcquisitionN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/A$3.00-11.50% DownsideSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51AHACAlpha Healthcare AcquisitionN/AN/A$0.12 per share92.25$0.39 per shareN/AAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21LOGCLogicBio Therapeutics$5.41M12.61N/AN/A$0.48 per share4.31MIROMiromatrix Medical$958.03K97.02N/AN/A$1.25 per share2.71Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/AAHACAlpha Healthcare Acquisition$1.42MN/A0.00∞N/AN/AN/AN/AN/AAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ALOGCLogicBio Therapeutics-$40.03M-$0.81N/AN/AN/A-246.71%-115.29%-53.01%N/AMIROMiromatrix Medical-$29.96M-$1.14N/A∞N/A-2,861.17%-120.49%-90.70%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AAHACAlpha Healthcare AcquisitionN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40AHACAlpha Healthcare AcquisitionN/A2.102.10AYLAAyala PharmaceuticalsN/A2.282.28LOGCLogicBio Therapeutics0.171.992.26MIROMiromatrix Medical0.023.463.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%AHACAlpha Healthcare Acquisition19.00%AYLAAyala Pharmaceuticals22.10%LOGCLogicBio Therapeutics39.11%MIROMiromatrix Medical29.38%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%AHACAlpha Healthcare AcquisitionN/AAYLAAyala Pharmaceuticals3.60%LOGCLogicBio Therapeutics8.10%MIROMiromatrix Medical5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableAHACAlpha Healthcare AcquisitionN/A12.86 millionN/ANot OptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableLOGCLogicBio Therapeutics6232.96 million30.29 millionNot OptionableMIROMiromatrix Medical7627.42 million25.99 millionOptionableLOGC, MIRO, AGTC, AHAC, and AYLA HeadlinesSourceHeadlineWalter Reed Army Medical Centermilitary.com - March 2 at 8:07 PMQ4 2023 United Therapeutics Corp Earnings Calluk.finance.yahoo.com - February 22 at 1:24 AMSouthwest Virginia scientists are gene-editing pigs for human transplantscardinalnews.org - December 19 at 9:31 AMBest Stocks to Buy Right Nowbenzinga.com - November 22 at 6:57 PMMiromatrix Holder Says It Omitted United Therapeutics Deal Infonews.bloomberglaw.com - November 16 at 7:25 PMMiromatrix Medical GAAP EPS of -$0.24, revenue of $11.17Mmsn.com - November 15 at 1:53 PMMiromatrix Reports Third Quarter 2023 Resultsfinance.yahoo.com - November 14 at 8:27 PMMiromatrix Medical climbs 225% following $140m United Therapeutics bidproactiveinvestors.com - October 31 at 10:31 PMUnited Therapeutics agrees to buy Miromatrix Medicalmsn.com - October 31 at 10:31 PMUnited Therapeutics looks to hog bioengineered organ R&D with $91M Miromatrix buyfiercebiotech.com - October 31 at 12:30 PMMiromatrix Medical Shares Triple After United Therapeutics Offermarketwatch.com - October 31 at 12:30 PMUnited Therapeutics buying Miromatrix for up to $140Mbioworld.com - October 30 at 8:55 PMEden Prairie biotech company Miromatrix Medical sells for $91Mstartribune.com - October 30 at 10:48 AMUnited Therapeutics to buy Miromatrix Medical for $3.25 per sharemsn.com - October 30 at 10:48 AMWhy Is Miromatrix Medical (MIRO) Stock Up 235% Today?investorplace.com - October 30 at 9:13 AMMiromatrix to Present at the 2023 ISODP Organ Donation Congressfinance.yahoo.com - October 11 at 7:34 PMMiromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesafinance.yahoo.com - October 5 at 6:16 PMSeveral Insiders Invested In Miromatrix Medical Flagging Positive Newsfinance.yahoo.com - September 10 at 5:39 PMMiromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshopfinance.yahoo.com - September 5 at 4:52 PMMiromatrix Medical Inc. (NASDAQ:MIRO) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 21 at 5:29 PMMiromatrix Medical Inc.: Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Updatefinanznachrichten.de - August 15 at 4:21 PMMiromatrix Medical GAAP EPS of -$0.24msn.com - August 15 at 4:21 PMCraig-Hallum Keeps Their Buy Rating on Miromatrix Medical (MIRO)markets.businessinsider.com - August 15 at 4:21 PMQ2 2023 Miromatrix Medical Inc Earnings Callfinance.yahoo.com - August 15 at 9:47 AMNew MarketBeat Followers Over TimeCompany DescriptionsApplied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.Alpha Healthcare AcquisitionNASDAQ:AHACAlpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.Ayala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.LogicBio TherapeuticsNASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Miromatrix MedicalNASDAQ:MIROMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.